Sales and profits grew solidly in 3Q and 1-3Q 2024, with strong performance in patient and clinical trial segments, improved margins, and continued leadership in customer satisfaction. Viking Global's investment in Humaneva and robust dividend payouts highlight strategic progress.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.